SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ARIAD Pharmaceuticals
ARIA 23.990.0%Feb 17 4:00 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: jaybe3/2/2016 9:14:18 PM
   of 4474
 
New commentary to Jan 14th Blood article on pona's impact with low-level mutations in CML...

“Response to ponatinib for CP-CML patients without the T315I mutation was similar, regardless of the number or type of mutations detected,” Dr. Parker explained. “This suggests that ponatinib may be a particularly effective therapeutic option for patients with multiple mutations (without T315I), as this subset of patients had substantially inferior response when treated with second-generation TKIs.”

ashclinicalnews.org
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News